References
- Palacios R, Patiño EG, de Oliveira Piorelli R, Conde M, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:853.
- Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, Chen HX. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20:891–98.
- Silpa-Archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016;100:135–41. doi:10.1136/bjophthalmol-2015-306629.
- Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rhumatol. 2002;29:288–91.
- Bonilla FA. Update: vaccines in primary immunodeficiency. J Allergy Clin Immunol. 2018;141:474–81. doi:10.1016/j.jaci.2017.12.980.
- Liu H, Zhang J, Zhou P, Sun H, Katsarou M, Drakoulis N. Exploration of vascular adhesion protein-1 expression in patients with conjunctivitis associated systemic lupus erythematosus using 2D-DIGE. Exp Ther Med. 2019;18:5072–77.
- Kuniyoshi K, Hatsukawa Y, Kimura S, Fujino T, Ohguro H, Nakai R, Sunami K, Mishima SI, Sato T, Kusaka S, et al. Acute bilateral photoreceptor degeneration in an infant after vaccination against measles and rubella. JAMA Ophthalmol. 2017;135:478–82.
- Cheng JY, Margo CE. Ocular adverse events following vaccination: overview and update. Surv Ophthalmol. 2021. doi:10.1016/j.survophthal.2021.04.001.